Weekly Recap: inaxaplin Phase 2b UACR/UPCR cuts and AMPLITUDE enrollment
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported Phase 2b AMPLIFIED results where inaxaplin 45 mg reduced UACR ~42.7% and UPCR ~44.7% in modest-proteinuria patients with favorable tolerability, modest T2D effects, mild transient transaminase rises in ~13%, and shares jumped ~2.4% as AMPLI…